Overview

Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)

Status:
Completed

Trial end date:
2020-12-17

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate the safety and tolerability of selonsertib, firsocostat, cilofexor, fenofibrate and/or Vascepa® in adults with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH).

Phase:

Phase 2

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Eicosapentaenoic acid ethyl ester
Fenofibrate
Firsocostat